Denise G Alfonso
Examiner (ID: 9637)
Most Active Art Unit | 2662 |
Art Unit(s) | 2662, 2663 |
Total Applications | 95 |
Issued Applications | 36 |
Pending Applications | 47 |
Abandoned Applications | 12 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16686770
[patent_doc_number] => 20210069245
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => MIRNA MODULATION OF T CELL SIGNALING AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/960529
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16960529
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/960529 | MIRNA MODULATION OF T CELL SIGNALING AND USES THEREOF | Jan 6, 2019 | Pending |
Array
(
[id] => 16728979
[patent_doc_number] => 20210096126
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => DIGITALIZED HUMAN ORGANOIDS AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 16/956230
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956230
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/956230 | DIGITALIZED HUMAN ORGANOIDS AND METHODS OF USING SAME | Dec 20, 2018 | Pending |
Array
(
[id] => 16720390
[patent_doc_number] => 20210087537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/954349
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954349
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/954349 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | Dec 20, 2018 | Pending |
Array
(
[id] => 18436421
[patent_doc_number] => 20230183715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => SHUTTLE PLASMID REPLICABLE IN CLOSTRIDIUM AND E. COLI AND RECOMBINANT MICROORGANISM PREPARED THEREWITH AND HAVING ENHANCED PENTOSE METABOLISM AND FERMENTATION PERFORMANCE
[patent_app_type] => utility
[patent_app_number] => 16/767931
[patent_app_country] => US
[patent_app_date] => 2018-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9990
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767931
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/767931 | SHUTTLE PLASMID REPLICABLE IN CLOSTRIDIUM AND E. COLI AND RECOMBINANT MICROORGANISM PREPARED THEREWITH AND HAVING ENHANCED PENTOSE METABOLISM AND FERMENTATION PERFORMANCE | Nov 27, 2018 | Pending |
Array
(
[id] => 16343951
[patent_doc_number] => 20200308601
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => EUKARYOTIC CELL LINE
[patent_app_type] => utility
[patent_app_number] => 16/759632
[patent_app_country] => US
[patent_app_date] => 2018-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7816
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759632
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/759632 | Eukaryotic cell line | Oct 24, 2018 | Issued |
Array
(
[id] => 16221273
[patent_doc_number] => 20200246389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLS
[patent_app_type] => utility
[patent_app_number] => 16/649522
[patent_app_country] => US
[patent_app_date] => 2018-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3812
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649522
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/649522 | METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLS | Sep 20, 2018 | Pending |
Array
(
[id] => 18683948
[patent_doc_number] => 11779658
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-10
[patent_title] => Expression vectors comprising engineered genes
[patent_app_type] => utility
[patent_app_number] => 16/622800
[patent_app_country] => US
[patent_app_date] => 2018-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 15586
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622800
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/622800 | Expression vectors comprising engineered genes | Jun 14, 2018 | Issued |
Array
(
[id] => 15832501
[patent_doc_number] => 20200131532
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => GENE THERAPY FOR OCULAR DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/607834
[patent_app_country] => US
[patent_app_date] => 2018-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607834
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/607834 | Gene therapy for ocular disorders | Apr 23, 2018 | Issued |
Array
(
[id] => 19043784
[patent_doc_number] => 11932870
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => Compositions and methods for immune cell modulation in adoptive immunotherapies
[patent_app_type] => utility
[patent_app_number] => 16/466265
[patent_app_country] => US
[patent_app_date] => 2017-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 28849
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16466265
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/466265 | Compositions and methods for immune cell modulation in adoptive immunotherapies | Dec 3, 2017 | Issued |
Array
(
[id] => 14375627
[patent_doc_number] => 20190161726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-30
[patent_title] => DIFFERENTIATED CELL PRODUCTION METHOD AND CULTURE BAG USED THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/321265
[patent_app_country] => US
[patent_app_date] => 2017-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16321265
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/321265 | DIFFERENTIATED CELL PRODUCTION METHOD AND CULTURE BAG USED THEREFOR | Jul 27, 2017 | Pending |
Array
(
[id] => 14069525
[patent_doc_number] => 20190083650
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => TKI PERMEABILITY ENHANCERS
[patent_app_type] => utility
[patent_app_number] => 15/527685
[patent_app_country] => US
[patent_app_date] => 2015-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19796
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15527685
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/527685 | TKI permeability enhancers | Nov 16, 2015 | Issued |